Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
90 participants
INTERVENTIONAL
2018-12-17
2024-12-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Sarilumab treatment for 12 months
2. Tocilizmab treatment for 12 months
3. Abatacept treatment for 12 months
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
NCT00124982
Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents
NCT01783730
Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy
NCT01021735
Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis
NCT05428488
A Retrospective Observational Study on the Use of Biologics in Monotherapy in Patients With Rheumatoid Arthritis
NCT01834807
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SAR, usually subucutaneous injection every 2 weeks
Drug: "Salirumab"
To examine the effects of salirumab in RA patients
Drug: "Tocilizmab"
To examine the effects of tocilizmab in RA patients
Drug: "Abatacept"
To examine the effects of abatacept in RA patients
TCZ, usually subucutaneous injection every 2 weeks
Drug: "Salirumab"
To examine the effects of salirumab in RA patients
Drug: "Tocilizmab"
To examine the effects of tocilizmab in RA patients
Drug: "Abatacept"
To examine the effects of abatacept in RA patients
ABT, usually subucutaneous injection every week
Drug: "Salirumab"
To examine the effects of salirumab in RA patients
Drug: "Tocilizmab"
To examine the effects of tocilizmab in RA patients
Drug: "Abatacept"
To examine the effects of abatacept in RA patients
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Drug: "Salirumab"
To examine the effects of salirumab in RA patients
Drug: "Tocilizmab"
To examine the effects of tocilizmab in RA patients
Drug: "Abatacept"
To examine the effects of abatacept in RA patients
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* RA patients who are allergic to the drugs, refused to do this research, or who are pregnant
20 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shinshu University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yukio Nakamura
Principle Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yukio Nakamura
Matsumoto, Nagano, Japan
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NonTNF 2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.